Abattis Bioceuticals Corp.

Equities

ATTBF

CA00258G1037

Healthcare Facilities & Services

Market Closed - OTC Markets Other stock markets 19:54:17 22/05/2024 BST			5-day change	1st Jan Change
0.000001 ^USD	0.00%		0.00%	0.00%

2020	Abattis Bioceuticals Corp. Reports Earnings Results for the Full Year Ended September 30, 2019	CI
2019	Abattis Bioceuticals Corp. Announces Board Changes	CI

Abattis Bioceuticals Corp. Appoints Robert Abenante as President and Chief Executive Officer

April 10, 2017 at 06:09 pm

Abattis Bioceuticals Corp. announced the appointment of Robert Abenante as President and Chief Executive Officer of the Company. Mr. Abenante is a seasoned executive with extensive public company experience.

Mr. Abenante is a Chartered Professional Accountant (CPA, CA) who also holds a Masters. After his tenures with PricewaterhouseCoopers and Deloitte, Mr. Abenante founded and/or served as an officer/director of several public and private companies across various industries, ranging from energy and mining to agriculture technology and nutraceuticals.

Latest news about Abattis Bioceuticals Corp.

Abattis Bioceuticals Corp. Reports Earnings Results for the Full Year Ended September 30, 2019	30/04/20	CI
Abattis Bioceuticals Corp. Announces Board Changes	08/11/19	CI
Abattis Bioceuticals Corp. (OTCPK:ATTB.F) cancelled the acquisition of NutriVida Corp.	07/11/19	CI
Abattis Bioceuticals Corp. Reports Earnings Results for the Third Quarter Ended June 30, 2019	27/08/19	CI
Abattis Bioceuticals Corp.'s Equity Buyback announced on August 7, 2018, has expired.	14/08/19	CI
Abattis Bioceuticals Corp. Reports Earnings Results for the Full Year Ended September 30, 2018	07/08/19	CI
Abattis Bioceuticals Corp. (OTCPK:ATTB.F) cancelled the acquisition of Winston Resources Inc..	27/06/19	CI
Abattis Bioceuticals Corp. (OTCPK:ATTB.F) completed the acquisition of Pro Natura BV from The Catalyst Capital Group Inc.	20/05/19	CI
Abattis Bioceuticals Corp. Announces Management Changes	02/04/19	CI
Abattis Bioceuticals Corp. (OTCPK:ATTB.F) agreed to acquire Pro Natura BV from The Catalyst Capital Group Inc. for €15.7 million.	01/04/19	CI
Abattis Bioceuticals Corp. Announces Resignations in Board	11/03/19	CI
British Columbia Securities Commission Removes Temporary Order on Abattis Bioceuticals Corp	17/01/19	CI
Abattis Bioceuticals Corp Announces Launch of Its New Website and Provide an Operational Update	21/12/18	CI
Abattis Bioceuticals Corp. (OTCPK:ATTB.F) signed a letter of intent to acquire NutriVida Corp. for CAD 15 million.	06/12/18	CI
Abattis Bioceuticals Corp Signs a Distribution Agreement with Shefield &Sons Tobacconists Inc. to Sell the Abattis Vaporizer Line in all Shefield &Sons Stores Across Canada	27/11/18	CI
Abattis Bioceuticals Corp. (OTCPK:ATTB.F) acquired Select Strains Inc. for $3.5 million.	22/11/18	CI
Abattis Bioceuticals Corp. Announces Executive Changes	21/11/18	CI
Abattis Intends To Seek Acquisitions	21/11/18	CI
Abattis Bioceuticals Corp. Announces Board Changes	18/10/18	CI
Abattis Bioceuticals Corp. Provides Update on Vaporizer Product Line	11/10/18	CI
Abattis Bioceuticals Provides Phase 1 Update on Research and Development for Nanoemulsification and Liposomal Platforms of Cannabinoid-Rich Hemp Oil	04/10/18	CI
Abattis Bioceuticals Corp. Announces the Pending Release of “Comfort”, A Nutraceutical Designed to Target Chronic Pain and Inflammation	24/09/18	CI
Abattis Bioceuticals Corp. Appoints Nicole Breitinger as Corporate Secretary	11/09/18	CI
Abattis Bioceuticals Corp. to Launch New Products Through Vergence Naturals	28/08/18	CI
Emerald Health Therapeutics, Inc. completed the acquisition of 35% stake in Northern Vine Canada Inc. from Abattis Bioceuticals Corp. (OTCPK:ATTB.F).	13/08/18	CI

Chart Abattis Bioceuticals Corp.

Duration

Period

More charts

Company Profile

Abattis Bioceuticals Corp. is a Canada-based specialty biotechnology company. The Company aggregates, incubates, integrates and invests in the natural health product and botanical drug development industry. It operates through the segment of producing, licensing and marketing ingredients and formulas for use in the biopharma, nutraceutical, cosmetic and animal nutrition markets. The Company, through its subsidiaries, develops and commercializes natural health (nutraceutical) products, and conducts research and development to create plant-based (botanical) intellectual property and ingredients for the pharmaceutical and bioceutical markets, among others. It offers products and services, such as botanical blends and formulas; cannabidiol ingredients; functional foods and beverages, and analytical services. It is focused on creating botanical formulations, medical marijuana and specialized health products for pain caused by inflammation, and mental ailments.

Sector

Healthcare Facilities & Services

More about the company

Sector Medical Farming

	1st Jan change	Capi.
ABATTIS BIOCEUTICALS CORP.	0.00%	476
CRUCIAL INNOVATIONS CORP.	-.--%	339M
AYR WELLNESS INC.	+41.56%	277M
ASCEND WELLNESS HOLDINGS, INC.	+22.68%	253M
ORGANIGRAM HOLDINGS INC.	+48.84%	194M
INTERCURE LTD.	+145.52%	144M
JUSHI HOLDINGS INC.	+46.30%	132M
THE CANNABIST COMPANY HOLDINGS INC.	-39.97%	123M
IANTHUS CAPITAL HOLDINGS, INC.	-28.57%	121M
4FRONT VENTURES CORP.	+7.69%	93.71M

Medical Farming